文献速递泌尿生殖腹部MR

MRI检测膀胱癌与前列腺癌淋巴结转移的诊断效能:更新的系统评价与诊断性Meta分析

The Diagnostic Performance of MRI for Detection of Lymph Node Metastasis in Bladder and Prostate Cancer: An Updated Systematic Review and Diagnostic Meta-Analysis.
PubMed 文献 · AJR Am J Roentgenol · 2018-01-30

该系统评价与诊断性Meta分析纳入24项研究共2928例患者,评估MRI检测膀胱癌或前列腺癌盆腔淋巴结转移的诊断准确性。汇总每例患者敏感度为0.56(95%CI 0.42-0.69),特异度为0.94(95%CI 0.90-0.96);每淋巴结汇总敏感度0.57(95%CI 0.29-0.82),特异度0.97(95%CI 0.94-0.98)。使用USPIO的研究敏感度0.86(95%CI 0.62-0.96)高于未使用USPIO者的0.46(95%CI 0.35-0.58)。

要点

  • MRI检测膀胱癌和前列腺癌盆腔淋巴结转移特异度高(每例患者0.94,每淋巴结0.97),但敏感度低且异质性大。
  • 每例患者汇总敏感度仅0.56(95%CI 0.42-0.69),提示MRI阴性不能排除淋巴结转移。
  • 使用USPIO的研究敏感度0.86(95%CI 0.62-0.96),高于未使用USPIO者的0.46(95%CI 0.35-0.58)。

核心结论

  • MRI检测膀胱癌和前列腺癌盆腔淋巴结转移显示高特异度,但敏感度低且异质性大;使用USPIO可提高敏感度。

研究设计与样本

  • 系统评价与诊断性Meta分析,检索MEDLINE和EMBASE至2017年1月13日,纳入24项研究共2928例患者,以2000年以来发表的组织病理学分析为参考标准,采用QUADAS-2工具评估方法学质量。

诊断标准与关键数值

  • 每例患者汇总(n=21)敏感度0.56(95%CI 0.42-0.69),特异度0.94(95%CI 0.90-0.96);每淋巴结汇总(n=9)敏感度0.57(95%CI 0.29-0.82),特异度0.97(95%CI 0.94-0.98);使用USPIO的研究(n=4)敏感度0.86(95%CI 0.62-0.96),未使用USPIO的研究(n=17)敏感度0.46(95%CI 0.35-0.58)。

临床应用与阅片要点

  • 原文结论指出MRI检测盆腔淋巴结转移特异度高但敏感度低且异质性大,使用USPIO可提高敏感度。

局限性

  • 敏感度估计值显示显著差异,而异质性受癌症类型、磁场强度和USPIO使用影响(p ≤ 0.01)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: The purpose of this article is to review the diagnostic performance of MRI for the detection of pelvic lymph node (LN) metastasis in patients with bladder and prostate cancer.

MATERIALS AND METHODS: MEDLINE and EMBASE were searched up to January 13, 2017. We included diagnostic accuracy studies that used MRI for pelvic LN detection in patients with bladder or prostate cancer, using histopathologic analyses published since 2000 as the reference standard. Two independent reviewers assessed the methodologic quality using the Quality Assessment of Diagnostic Accuracy Studies-2 tool. Sensitivity and specificity of all studies were calculated. Per-patient and per-LN results were pooled and plotted in a hierarchic summary ROC plot. Metaregression, sensitivity, and subgroup analyses were performed.

RESULTS: Twenty-four studies (2928 patients) were included. Pooled per-patient sensitivity (n = 21) was 0.56 (95% CI, 0.42-0.69) with a specificity of 0.94 (95% CI, 0.90-0.96). Per-LN pooled estimates (n = 9) showed consistent results: sensitivity of 0.57 (95% CI, 0.29-0.82) and specificity of 0.97 (95% CI, 0.94-0.98). At metaregression analysis, type of cancer, magnet field strength, and use of ultrasmall superparamagnetic particles of iron oxide (USPIO) were significant factors affecting heterogeneity (p ≤ 0.01). Sensitivity analyses showed that specificity estimates were comparable (range, 0.87-0.95), but sensitivity estimates showed significant differences. Studies that used USPIO (n = 4) had higher sensitivity (0.86; 95% CI, 0.62-0.96) than did those not using USPIO (n = 17; 0.46; 95% CI, 0.35-0.58).

CONCLUSION: MRI shows high specificity but poor and heterogeneous sensitivity for detecting pelvic LN metastasis in patients with bladder and prostate cancer. Using USPIO can improve sensitivity.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Woo S, Suh CH, Kim SY, et al. The Diagnostic Performance of MRI for Detection of Lymph Node Metastasis in Bladder and Prostate Cancer: An Updated Systematic Review and Diagnostic Meta-Analysis. AJR Am J Roentgenol. 2018. PMID: 29381380. doi:10.2214/AJR.17.18481

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。